Latest Health News

PYC Therapeutics has completed dosing in its Phase 1 study of PYC-001 for Autosomal Dominant Optic Atrophy, showing strong safety and early signs of improved vision. The company plans to launch a global Phase 1/2 trial later this year.

Wesfarmers Limited has updated its dividend details, confirming a fully franked ordinary dividend of AUD 1.11 per share payable on 7 October 2025, with shareholders able to receive payments in AUD, NZD, or GBP.

The Calmer Co. reports a significant operational turnaround in H2 FY25, with sales momentum building through July and August, driven by cost reductions and new product launches in the US market.

Haranga Resources has successfully commissioned the water treatment plant at its Lincoln Gold Project and begun dewatering, paving the way for its maiden underground drilling program and a JORC resource update by year-end.

Tasmea Limited has firmly denied recent media speculation about potential block trades by its executive directors, reaffirming their strong shareholding and commitment to growth. The company is focused on organic expansion and acquisitions to secure ASX 300 inclusion next year without raising new capital.

Biome Australia Limited projects its Q1 FY26 sales revenue to exceed $5.5 million, breaking its previous quarterly record and signaling continued momentum in the microbiome health sector.

OM Holdings reported steady revenue of US$309.3 million in 1H 2025 despite a sharp EBITDA decline and net loss, while maintaining a strong cash position and advancing sustainability goals.

NRW Holdings has agreed to acquire Fredon Industries for up to $200 million, introducing a new strategic pillar and broadening its service capabilities in energy transition and infrastructure. The deal is expected to complete by September 30, 2025, with strong earnings visibility for FY26.

NRW Holdings has agreed to acquire Fredon Industries for up to $200 million, significantly broadening its electrical, mechanical, infrastructure, and technology services. The deal is expected to boost NRW’s earnings and open new growth avenues tied to energy transition and digital innovation.

Advanced Braking Technology (ABT) reported robust FY25 financial results marked by revenue growth and improved profitability, while advancing its strategic roadmap focused on mining safety innovations and global market expansion.

Race Oncology has activated its first clinical trial site in Hong Kong for the Phase 1 study of RC220 combined with doxorubicin in advanced solid tumours, marking a significant step in accelerating patient enrolment and broadening clinical data.

TALi Digital has successfully placed 446 million shares to close the shortfall from its recent entitlement offer, raising $446,000. The company also highlights its strategic acquisition of You Can Do It! Education, expanding its reach in digital health and social-emotional learning.